

Nasopain™

Naproxen + Esomeprazole

Composition:

Nasopain™ 375/20 Tablet: Each delayed release enteric coated tablet contains Naproxen USP 375 mg and Esomeprazole Magnesium Trihydrate USP equivalent to Esomeprazole 20 mg.

Nasopain™ 500/20 Tablet: Each delayed release enteric coated tablet contains Naproxen USP 500 mg and Esomeprazole Magnesium Trihydrate USP equivalent to Esomeprazole 20 mg.

Description:

Naproxen is a non-steroidal anti-inflammatory agent. This drug exhibits anti-inflammatory, analgesic and antipyretic activity. Naproxen is an inhibitor of prostaglandin synthesis.

Esomeprazole is the S-isomer of the proton pump inhibitor omeprazole. It is a potent suppressor of gastric acid secretion. It inhibits the gastric H⁺, K⁺-ATPase (proton pump). Esomeprazole inhibits the final step in the secretion of gastric acid.

Indications:

Nasopain™ (Naproxen + Esomeprazole) is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

Dosage & Administration:

Rheumatoid Arthritis, Osteoarthritis and Ankylosing Spondylitis: The dosage is one tablet twice daily at least 30 minutes before meals.

OR AS DIRECTED BY THE PHYSICIAN.

Side Effects:

The most common side effects are upper abdominal pain, duodenal ulcer & erosive gastritis. Other side effects are dyspepsia, diarrhea, nausea, flatulence, constipation, headache, dysgeusia, cough, dizziness, peripheral edema, dry mouth, insomnia, drowsiness, malaise, blurred vision, rash & pruritis.

Precautions:

Should be used with caution in patients with hypertension, fluid retention, heart failure, advanced renal disease, liver disease & history of inflammatory bowel disease (ulcerative colitis, Crohn's disease). Blood pressure should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy. If active and clinically significant bleeding from any source occurs in patients receiving Naproxen & Esomeprazole combination, the treatment should be withdrawn.

Pregnancy and Lactation:

Nasopain should be used during pregnancy only if the potential benefits justify the potential risks to the fetus.

Contraindications:

This combination is contraindicated in patients with known hypersensitivity to Naproxen, Esomeprazole or to any other components of this preparation. It is also contraindicated in patients who have experienced asthma, urticaria or allergic-type reactions after taking aspirin or other NSAIDs and for the treatment of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Drug Interaction:

NSAIDs may diminish the effect of ACE-inhibitors, furosemide and thiazides. NSAIDs may increase the effects of warfarin. Concomitant administration of cholestyramine can delay the absorption of Naproxen.

Storage Condition:

Store in a cool & dry place, protect from light. Keep out of the reach of children.

Presentation:

Nasopain™ 375/20 Tablet: Each box contains 5 X 6's tablets in blister pack.

Nasopain™ 500/20 Tablet: Each box contains 5 X 6's tablets in blister pack.

Manufactured by:

Julphar Bangladesh Ltd.

Sreepur, Gazipur, Bangladesh.